Surrey researchers Sign in
Back
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Journal article

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

D Russell-Jones, A Vaag, O Schmitz, BK Sethi, N Lalic, S Antic, M Zdravkovic, GM Ravn, R Simó and Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Stud
Diabetologia, Vol.52(10), pp.2046-2055
10/2009
DOI: https://doi.org/10.1007/s00125-009-1472-y

Abstract

Adolescent Adult Aged Aged 80 and over Blood Glucose Body Weight Diabetes Mellitus Type 2 Drug Therapy Combination Female Glucagon-Like Peptide 1 Humans Hypoglycemic Agents Insulin Insulin Long-Acting Male Metformin Middle Aged Placebos Sulfonylurea Compounds Young Adult
The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride.

Metrics

36 Record Views
631 Times Cited - Web of Science

Details

Usage Policy

Usage details for all content viewed and downloaded in this site are shared with IRUS-UK (Institutional Repository Usage Statistics UK). Cookies are used to remember your decision. Click Accept to accept usage details sharing and the cookies.

Learn more